Synapse - Komal Jhaveri

Results (203)

Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)

Meeting Abstract

Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
Cancer Research (2021)

Fulltext@MSK | Save

A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)

Meeting Abstract

Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)

Meeting Abstract

Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
Cancer Research (2021)

Fulltext@MSK | Save

Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Jhaveri, K.; Juric, D.; Varga, A.; Turner, N.; Schmid, P.; Saura, C.; Oliveira, M.; Krop, I. E.; Kalinsky, K.; Italiano, A.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Latest findings from the breast cancer cohort in SUMMIT - A phase 2 'basket' trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer

Meeting Abstract

Jhaveri, K.; Saura, C.; Guerrero-Zotano, A.; Spanggaard, I.; Bidard, F. C.; Goldman, J. W.; Garcia-Sáenz, J. A.; Cervantes, A.; Boni, V.; Crown, J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)